Clarification: Current Status of Neuromuscular Reversal and Monitoring, Challenges and Opportunities

We are writing to clarify certain statements and information provided in a recent review of neuromuscular reversal and monitoring.¹ 

The article stated that, “The GE Healthcare E-NMT-01 module was recalled by the FDA in 2014.” To clarify, GE Healthcare initiated the recall voluntarily, and the announcement appeared on the U.S. Food and Drug Administration Web site. This voluntary recall action entailed technology correction and replacement of all modules in the field. It was completed September 28, 2015. The GE Healthcare NeuroMuscular Transmission (NMT) module is commercially available. Additional information is available on the U.S. Food and Drug Administration Web site.² 

The article also incorrectly showed that the GE Healthcare M-NMT module has only a kinemyography sensor and that the E-NMT module has only an electromyography sensor. To clarify, both the M-NMT and E-NMT modules had interchangeable electromyography and kinemyography sensors. The M-NMT module is no longer manufactured and was replaced by the currently available E-NMT module. We emphasize the clinical benefits that can be afforded from routine use of objective neuromuscular monitors.^3,4 

Support was provided solely from institutional and/or departmental sources.

Ms. Hyman is employed by GE Healthcare (Chicago, Illinois). Dr. Brull is a shareholder and member of the Board of Directors of Senzime AB (Uppsala, Sweden).